UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 246

Sortiert nach

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

Bone marrow transplantation (Basingstoke), 2020-09, Vol.55 (9), p.1810-1816

2020

Volltextzugriff (PDF)

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4521-4530

2010

Volltextzugriff (PDF)

The Genetic Architecture of Multiple Myeloma

Advances in Hematology, 2014, Vol.2014 (2014), p.864058-16

2014

Volltextzugriff (PDF)

Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT

British journal of haematology, 2020-06, Vol.189 (5), p.e213-e217

2020

Volltextzugriff (PDF)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma

Cell reports. Medicine, 2022-02, Vol.3 (2), p.100508-100508, Article 100508

2022

Volltextzugriff (PDF)

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population

British journal of haematology, 2014-03, Vol.164 (5), p.684-693

2014

Volltextzugriff (PDF)

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21

European journal of haematology, 2016-01, Vol.96 (1), p.46-54

2016

Volltextzugriff (PDF)

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

Journal of clinical oncology, 2011-08, Vol.29 (22), p.3016-3022

2011

Volltextzugriff (PDF)

Efficacy and outcome of autologous transplantation in rare myelomas

Haematologica (Roma), 2010-12, Vol.95 (12), p.2126-2133

2010

Volltextzugriff (PDF)

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation

British journal of haematology, 2010-01, Vol.148 (2), p.323-331

2010

Volltextzugriff (PDF)

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting

Leukemia & lymphoma, 2017-04, Vol.58 (4), p.797-808

2017

Volltextzugriff (PDF)

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

Leukemia & lymphoma, 2016-06, Vol.57 (6), p.1256-1268

2016

Volltextzugriff (PDF)

Approach to the treatment of multiple myeloma: a clash of philosophies

Blood, 2011-09, Vol.118 (12), p.3205-3211

2011

Volltextzugriff (PDF)

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

Blood, 2007-04, Vol.109 (8), p.3588-3594

2007

Volltextzugriff (PDF)

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

PloS one, 2014-07, Vol.9 (7), p.e101819-e101819

2014

Volltextzugriff (PDF)

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

British journal of haematology, 2021-08, Vol.194 (3), p.496-507

2021

Volltextzugriff (PDF)

Case Report: Treatment of light‐chain amyloidosis with daratumumab monotherapy in two patients

European journal of haematology, 2018-04, Vol.100 (4), p.386-388

2018

Volltextzugriff (PDF)

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

European journal of haematology, 2019-12, Vol.103 (6), p.588-596

2019

Volltextzugriff (PDF)

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Journal of clinical oncology, 2012-07, Vol.30 (20), p.2475-2482

2012

Volltextzugriff (PDF)

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care

European journal of haematology, 2022-12, Vol.109 (6), p.749-754

2022

Volltextzugriff (PDF)

Response to Caravita di Toritto and Rago

European journal of haematology, 2023-02, Vol.110 (2), p.224-225

2023

Volltextzugriff (PDF)

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Blood cancer journal (New York), 2021-12, Vol.11 (12), p.192-192, Article 192

2021

Volltextzugriff (PDF)

1 – 25 von 246

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(165)
Science & Technology
(156)
Life Sciences & Biomedicine
(152)
Medicin Och Hälsovetenskap
(101)
Hematology
(93)
Male
(85)
Middle Aged
(82)
Biological And Medical Sciences
(81)
Female
(80)
Medical Sciences
(79)
Adult
(67)
Aged
(50)
Oncology
(50)
Hematologic And Hematopoietic Diseases
(41)
Multiple Myeloma
(40)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(39)
Multiple Myeloma - Therapy
(35)
Bone Marrow Transplantation
(31)
Prognosis
(30)
Transplantation, Homologous
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

The Genetic Architecture of Multiple Myeloma

Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

Efficacy and outcome of autologous transplantation in rare myelomas

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation

Challenges in Vector and Trial Design Using Retroviral Vectors for Long-Term Gene Correction in Hematopoietic Stem Cell Gene Therapy

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

Approach to the treatment of multiple myeloma: a clash of philosophies

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Case Report: Treatment of light‐chain amyloidosis with daratumumab monotherapy in two patients

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care

Response to Caravita di Toritto and Rago

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Suchergebnisse filtern